Elutia Q2 FY26 net loss narrows 20.4% to $7.6 million; net sales fall 11.7% to $2.4 million
ELUT•Q2 FY26 results
- Elutia posted a GAAP net loss of $7.6 million for Q2 2026, narrowing from $9.6 million a year earlier.
- Net sales fell 11.65% to $2.4 million, reflecting a $0.7 million SimpliDerm revenue drop partly offset by a $0.4 million cardiovascular gain.
- GAAP gross margin rose 6.7 percentage points to 59.6%.
- Operating loss narrowed to $8 million from $8.4 million; total operating expenses eased to $9.4 million from $9.8 million.
- Secured up to $26 million without an equity offering; NXT-41 FDA decision expected 4Q 2026, NXT-41x expected 1H 2027.
